Circulatory monitoring systems and methods

• US 20090157057A1
• Filed: 05/19/2008
• Published: 06/18/2009
• Est. Priority Date: 12/18/2007
• Status: Abandoned Application

• Current Assignee: Gearbox LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC A Limited Liability Corporation of The State of Delaware
• Inventors: Ishikawa, Muriel Y., Ferren, Bran, Wood, Lowell L. JR., Rivet, Dennis J., Hyde, Roderick A., Wood, Victoria Y.H., Leuthardt, Eric C., Hagen, Jeffrey John
• Application Number:
  US12/154,140
• Publication Number:
  US 20090157057A1
• Time in Patent Office: Days
• US Class Current: 604/891.100
• CPC Class Codes: A61B 2562/02 Details of sensors specially adapted for in-vivo measurements
• CPC Class Codes: A61B 2562/0233 Special features of optical sensors or probes classified in A61B5/00
• CPC Class Codes: A61B 2562/0247 Pressure sensors
• CPC Class Codes: A61B 2562/046 in a matrix array
• CPC Class Codes: A61B 5/0031 Implanted circuitry
• CPC Class Codes: A61B 5/015 By temperature mapping of body part
• CPC Class Codes: A61B 5/0205 Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• CPC Class Codes: A61B 5/02055 Simultaneously evaluating both cardiovascular condition and temperature
• CPC Class Codes: A61B 5/026 Measuring blood flow A61B3/1233, A61B3/1241 take precedence
• CPC Class Codes: A61B 5/412 Detecting or monitoring sepsis
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: A61B 5/6804 Garments; Clothes
• CPC Class Codes: A61B 5/6807 Footwear
• CPC Class Codes: A61B 5/6833 Adhesive patches
• CPC Class Codes: A61B 5/6843 Monitoring or controlling sensor contact pressure
• CPC Class Codes: A61B 5/6848 Needles
• CPC Class Codes: A61B 5/6862 Stents
• CPC Class Codes: A61B 5/6876 Blood vessel
• CPC Class Codes: A61B 5/6887 mounted on external non-worn devices, e.g. non-medical devices
• CPC Class Codes: A61B 8/06 : Measuring blood flow measuring volume flow in general G01F, e.g. G01F1/66, G01F1/72; measuring speed of fluids in general G01P5/00
• CPC Class Codes: A61B 8/4472 : Wireless probes
• CPC Class Codes: A61B 8/4483 : characterised by features of the ultrasound transducer
• CPC Class Codes: A61F 2250/0002 : for data transfer
• CPC Class Codes: A61M 2005/1726 : the body parameters being measured at, or proximate to, the infusion site
• CPC Class Codes: A61M 2025/1052 : for temporarily occluding a vessel for isolating a sector
• CPC Class Codes: A61M 2039/2413 : designed to reduce and or shut-off the flow when a certain maximum flow limit is exceeded
• CPC Class Codes: A61M 2039/242 : designed to open when a predetermined pressure or flow rate has been reached, e.g. check valve actuated by fluid
• CPC Class Codes: A61M 2039/248 : Ball-valve
• CPC Class Codes: A61M 2205/04 : implanted
• CPC Class Codes: A61M 2205/3507 : with implanted devices, e.g. external control
• CPC Class Codes: A61M 2205/3561 : local, e.g. within room or hospital
• CPC Class Codes: A61M 2205/3592 : using telemetric means, e.g. radio or optical transmission
• CPC Class Codes: A61M 31/00 : Devices for introducing or retaining media, e.g. remedies, in cavities of the body A61M25/00 takes precedence ; introducing or retaining ophthalmic products into the ocular cavities A61F9/0008
• CPC Class Codes: A61M 39/24 : Check- or non-return valves
• CPC Class Codes: A61M 5/14276 : specially adapted for implantation
• CPC Class Codes: A61M 5/16831 : Monitoring, detecting, signalling or eliminating infusion flow anomalies low-level float-valves causing cut-off A61M5/40; indicating or recording presence, absence or direction of flow in general G01P13/0066
• CPC Class Codes: A61M 5/1723 : using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: G16H 40/63 : for local operation
• CPC Class Codes: G16Z 99/00 : Subject matter not provided for in other main groups of this subclass

Abstract

Systems and methods are described for obtaining and acting upon information indicative of circulatory health and related phenomena in human beings or other subjects. Some involve implementing or deploying therapeutic administration systems, for example, for obtaining a priori implant information and signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants; or obtaining a flow-change-indicative measurement and signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement; or obtaining one or more indications of a lytic material in a vicinity of one or more body lumens and accelerating a decrease in a local concentration of the lytic material in the vicinity of the one or more body lumens by causing one or more elements to extract at least a portion of the lytic material in the vicinity of the one or more body lumens in response to the one or more indications of the lytic material in the vicinity of the one or more body lumens; or one or more capture components configured to accelerate a decrease in a local concentration of one or more therapeutic structures along a downstream portion of a vasculature and one or more dispensation components configured to release the one or more therapeutic structures into an upstream portion of the vasculature.

Claims

1. A therapeutic administration system comprising:

circuitry for obtaining a priori implant information; and

circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants.

2. The therapeutic administration system of claim 1 in which the circuitry for obtaining a priori implant information comprises:

circuitry for obtaining the a priori implant information from one or more implantable devices.

3. The therapeutic administration system of claim 1 in which the circuitry for obtaining a priori implant information comprises:

circuitry for obtaining the a priori implant information from one or more objects borne by a subject.

4. The therapeutic administration system of claim 1 in which the circuitry for obtaining a priori implant information comprises:

circuitry for obtaining the a priori implant information ex situ.

5. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants.

6. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to an implant type.

7. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

8. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to detecting one or more emboli.

9. The therapeutic administration system of claim 1 in which the circuitry for obtaining a priori implant information comprises:

circuitry for obtaining an update for the a priori implant information.

10. The therapeutic administration system of claim 1 in which the circuitry for obtaining a priori implant information comprises:

circuitry for obtaining timing information in the a priori implant information.

11. The therapeutic administration system of claim 1 in which the circuitry for obtaining a priori implant information comprises:

circuitry for obtaining an implant type of the a priori implant information.

12. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to an apparent change in a chemical composition.

13. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for signaling a decision whether to dispense one or more therapeutic materials from an implant.

14. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant.

15. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to an apparent change in vascular flow.

16. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for obtaining one or more ischemia indicators of the one or more other clot-indicative determinants.

17. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

a flow-force-responsive element.

18. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

one or more of a reflectance sensor or a transmittance sensor.

19. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

one or more of a sonic sensor or an ion sensor.

20. The therapeutic administration system of claim 1, further comprising:

a wireless-communication device.

21. The therapeutic administration system of claim 1, further comprising:

an implant-site-targeting dispenser responsive to the decision whether to initiate the implant-site-targeting treatment.

40. The therapeutic administration system of claim 1 in which the circuitry for obtaining a priori implant information comprises:

circuitry for obtaining the a priori implant information from one or more implantable devices;

circuitry for obtaining the a priori implant information ex situ;

circuitry for obtaining an update for the a priori implant information;

circuitry for obtaining timing information in the a priori implant information; and

circuitry for obtaining an implant type.

41. The therapeutic administration system of claim 40 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to one or more of an apparent change in a chemical composition, an apparent change in vascular flow, the implant type, or detecting one or more emboli;

circuitry for signaling a decision whether to dispense one or more therapeutic materials from an implant;

circuitry for signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant;

circuitry for obtaining one or more ischemia indicators of the one or more other clot-indicative determinants;

one or more of a reflectance sensor or a transmittance sensor;

one or more of a sonic sensor or an ion sensor;

circuitry for obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants; and

circuitry for deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

42. The therapeutic administration system of claim 1 in which the circuitry for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

circuitry for generating the decision whether to initiate the implant-site-targeting treatment partly in response to one or more of an apparent change in a chemical composition, an apparent change in vascular flow, an implant type, or detecting one or more emboli;

circuitry for signaling a decision whether to dispense one or more therapeutic materials from an implant;

circuitry for signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant;

circuitry for obtaining one or more ischemia indicators of the one or more other clot-indicative determinants;

one or more of a reflectance sensor or a transmittance sensor;

one or more of a sonic sensor or an ion sensor;

circuitry for obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants; and

circuitry for deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

22-39. -39. (canceled)

43. A therapeutic administration system comprising:

means for obtaining a priori implant information; and

means for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants.

45. The therapeutic administration system of claim 43 in which the means for obtaining a priori implant information comprises:

means for obtaining the a priori implant information from one or more objects borne by a subject.

50. The therapeutic administration system of claim 43 in which the means for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

means for generating the decision whether to initiate the implant-site-targeting treatment partly in response to detecting one or more emboli.

59. The therapeutic administration system of claim 43 in which the means for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

a flow-force-responsive element.

81. The therapeutic administration system of claim 43 in which the means for obtaining a priori implant information comprises:

means for obtaining the a priori implant information from one or more implantable devices;

means for obtaining the a priori implant information ex situ;

means for obtaining an update for the a priori implant information;

means for obtaining timing information in the a priori implant information; and

means for obtaining an implant type.

82. The therapeutic administration system of claim 81 in which the means for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

means for generating the decision whether to initiate the implant-site-targeting treatment partly in response to one or more of an apparent change in a chemical composition, an apparent change in vascular flow, the implant type, or detecting one or more emboli;

means for signaling a decision whether to dispense one or more therapeutic materials from an implant;

means for signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant;

means for obtaining one or more ischemia indicators of the one or more other clot-indicative determinants;

means for detecting one or more of a reflectance or a transmittance;

means for obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants; and

means for deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

83. The therapeutic administration system of claim 43 in which the means for signaling a decision whether to initiate implant-site-targeting treatment partly based on the a priori implant information and partly based on one or more other clot-indicative determinants comprises:

means for generating the decision whether to initiate the implant-site-targeting treatment partly in response to one or more of an apparent change in a chemical composition, an apparent change in vascular flow, an implant type, or detecting one or more emboli;

means for signaling a decision whether to dispense one or more therapeutic materials from an implant;

means for signaling a decision whether to dispense one or more of a thrombolytic agent or an anticoagulant;

means for obtaining one or more ischemia indicators of the one or more other clot-indicative determinants;

means for detecting one or more of a reflectance sensor or a transmittance;

means for obtaining one or more of a blood pressure indicator or a flow rate indicator of the one or more other clot-indicative determinants; and

means for deciding whether to transmit one or more other treatment indications partly based on one or more hemorrhagic-stroke-indicative determinants.

44. (canceled)

46-49. -49. (canceled)

51-58. -58. (canceled)

60-80. -80. (canceled)